Rapport Therapeutics, Inc. (RAPP)
| Market Cap | 1.37B +13.8% |
| Revenue (ttm) | 20.00M |
| Net Income | -150.47M |
| EPS | -3.18 |
| Shares Out | 59.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 437,695 |
| Open | 23.23 |
| Previous Close | 23.59 |
| Day's Range | 23.00 - 23.83 |
| 52-Week Range | 22.06 - 52.93 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 64.21 (+177.25%) |
| Earnings Date | Nov 4, 2026 |
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorde... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for RAPP stock is "Strong Buy." The 12-month stock price target is $64.21, which is an increase of 177.25% from the latest price.
News
Rapport Therapeutics Transcript: Jefferies Global Healthcare Conference
RAP-219 showed seizure reductions of 71% electrographically and 78% clinically, plus positive Phase II bipolar mania results. Phase III programs and a monthly injectable are advancing, with cash runway through 2029.
Rapport Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
RAP-219’s epilepsy phase III trials are progressing, with ~$815M in cash funding trials through end-2029. Bipolar phase II results support plans for an FDA meeting early next year and two parallel phase III trials; an injectable readout is expected in Q3 next year.
Rapport Therapeutics price target lowered to $64 from $71 at UBS
UBS analyst Joon Lee lowered the firm’s price target on Rapport Therapeutics (RAPP) to $64 from $71 and keeps a Buy rating on the shares.
Rapport Therapeutics price target lowered to $66 from $70 at Guggenheim
Guggenheim lowered the firm’s price target on Rapport Therapeutics (RAPP) to $66 from $70 and keeps a Buy rating on the shares.
Rapport Therapeutics price target lowered to $47 from $50 at Wells Fargo
Wells Fargo lowered the firm’s price target on Rapport Therapeutics (RAPP) to $47 from $50 and keeps an Overweight rating on the shares. The firm thinks the bull case on…
Rapport Therapeutics reports Q3 EPS (84c), consensus ($1.22)
“We continue to deliver on our priorities with strong execution across the portfolio,” said Abraham N. Ceesay, chief executive officer of Rapport. “Our positive Phase 2 results in bipolar mania…
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label long-term safety tri...
Rapport Therapeutics Earnings release: Q3 2026
Rapport Therapeutics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Rapport Therapeutics Quarterly report: Q3 2026
Rapport Therapeutics has published its Q3 2026 quarterly earnings report on November 4, 2026.
Rapport Therapeutics to Participate in Upcoming Investor Conferences
BOSTON and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
BOSTON and SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Citizens biotech analysts hold an analyst/industry conference call
Biotech Analysts discuss novel therapies and novel mechanisms for Bipolar Mania (RAPP) on an Analyst/Industry conference call to be held on November 4.
Rapport Therapeutics 8.333M share Spot Secondary priced at $21.00
The deal range was $21.00-$22.00. Morgan Stanley, Leerink and Evercore ISI acted as joint book running managers for the offering.
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
BOSTON and SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Rapport announces $200M common stock, $150M convertible senior notes offerings
Rapport Therapeutics (RAPP) announced that it has commenced separate underwritten public offerings of $200M of shares of its common stock and $150M aggregate principal amount of convertible senior not...
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
BOSTON and SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Rapport Therapeutics price target raised to $70 from $65 at Guggenheim
Guggenheim raised the firm’s price target on Rapport Therapeutics (RAPP) to $70 from $65 and keeps a Buy rating on the shares after the company’s Phase 2 trial in bipolar…
Rapport Therapeutics price target raised to $82 from $50 at Jones
Jones raised the firm’s price target on Rapport Therapeutics (RAPP) to $82 from $50 and keeps a Buy rating on the shares. The company’s lead asset RAP-219 met its primary…
Rapport Therapeutics price target lowered to $50 from $51 at Wells Fargo
Wells Fargo lowered the firm’s price target on Rapport Therapeutics (RAPP) to $50 from $51 and keeps an Overweight rating on the shares. The firm sees RAP-219 emerging as an…
Rapport Therapeutics price target raised to $91 from $80 at Citizens
Citizens analyst Jason Butler raised the firm’s price target on Rapport Therapeutics (RAPP) to $91 from $80 and keeps an Outperform rating on the shares following the Phase 2 trial…
Rapport Therapeutics price target raised to $86 from $75 at Raymond James
Raymond James raised the firm’s price target on Rapport Therapeutics (RAPP) to $86 from $75 and keeps a Strong Buy rating on the shares. With shares trading roughly flat following…
Rapport Therapeutics price target raised to $66 from $40 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Rapport Therapeutics (RAPP) to $66 from $40 and keeps a Buy rating on the shares. RAP-219 met both primary…
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging
Positive trial data for Rapport's lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak sales opportunity, Jefferies says.
Rapport Therapeutics Transcript: Study result
RAP-219 met both phase II endpoints in bipolar mania, with improving YMRS and CGI results over three weeks and a well-tolerated profile. Phase III is anticipated in H2 2027, with dose and study-design refinements under consideration.
Rapport Therapeutics Press release: Study result
Rapport Therapeutics issued a press release on October 20, 2026, disclosing material business information to investors.